The National Health Fund (NHF) has announced that effective March 27, 2025, attention deficit hyperactivity disorder (ADHD) and cervical cancer are covered on the NHF's Card Programme, bringing the ...

Operator: Good afternoon, and welcome to the Evoke Pharma, Inc. Fourth Quarter and Full Year 2024 Earnings Conference Call. Currently, all callers have been placed in a listen-only mode.

The company developed, commercialized and markets GIMOTI, a nasal spray formulation of metoclopramide, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults.